Last reviewed · How we verify
IMC-18F1
At a glance
| Generic name | IMC-18F1 |
|---|---|
| Also known as | Icrucumab, LY3012212 |
| Sponsor | Eli Lilly and Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma (PHASE2)
- Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients (PHASE2)
- A Study of Ramucirumab or Icrucumab in Colorectal Cancer (PHASE2)
- Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMC-18F1 CI brief — competitive landscape report
- IMC-18F1 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI